Research and Development
We are supporting national research dedicated to understanding COVID-19 and improving the outcome for patients.
A national treatment trial has been set up to establish whether COVID-19 convalescent plasma benefits patients and at what point in their illness they should be treated.
Find out more about the convalescent plasma treatment trials and other COVID-19 related research
Our world-leading research programme
The success of NHS Blood and Transplant (NHSBT)'s strategy to achieve long-term improvements in patient outcomes requires an innovative research programme. The effective application of novel technologies, processes and products drives the advancement of clinical practice, but this can only be accomplished by having an integrated Research and Development (R&D) programme which supports organisational priorities. This requirement to undertake or commission R&D is an integral part of NHSBT’s mission, and is key to improving outcomes.
Our R&D programme is unique
Within the public, private and academic sectors there are no other organisations capable of delivering an R&D programme that spans our range of products and services. This is due to the combination of our partnerships with top-class universities, our clearly defined operational objectives and our expertise in translating research into new products, services and clinical guidelines.
Our R&D programme underpins NHSBT's business strategies and guides international transfusion and transplantation practice. The 2015–2020 R&D Strategy sets out innovative plans in support of Blood 2020, Taking Organ Transplantation to 2020 and our operating strategies in Diagnostic and Therapeutic Services.
To read about how our research is informing clinical practice and making a difference to patient outcomes, please read about our Research Themes.